{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T14:51:44Z","timestamp":1787755904238,"version":"build-2784847793"},"reference-count":51,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Pediatric brain tumors\u2014particularly pediatric low-grade gliomas (pLGG)\u2014represent a major survivorship inequity between high-income countries (HICs) and low- and middle-income countries (LMICs). While pLGG is highly curable in optimal-resource settings, outcomes in LMICs remain suboptimal due to delays in diagnosis, limited neurosurgical capacity, restricted access to molecular testing, and significant variability in pathology accuracy and treatment accessibility. Data from international pathology review programs highlight a major diagnostic challenge: misclassification rates of 18\u201332% for pediatric CNS tumors, with discrepancies often driven by limited neuropathology expertise and lack of essential tools such as immunohistochemistry and molecular profiling. Studies from both global outreach networks and single-institution reviews consistently demonstrate that brain tumors account for the majority of major disagreements, and that molecular markers such as BRAF alterations and H3 mutations are critical for accurate diagnosis and risk stratification. These gaps directly affect treatment decisions and outcomes. At the same time, pLGG treatment paradigms are shifting with the development of oral targeted MAPK-pathway inhibitors, which deliver high response rates with favorable toxicity profiles. These agents hold unique promise for LMIC settings because they avoid the need for prolonged intravenous chemotherapy and reduce dependence on central lines and high-intensity supportive care. However, widespread adoption is limited by cost, regulatory barriers, absence from essential drug lists, and lack of molecular diagnostics required to select patients who would benefit most. This review synthesizes evidence from the evolving pLGG diagnostic and therapeutic landscape, and applies the Global Initiative for Childhood Cancer (GICC) CureAll framework to pediatric neuro-oncology care in LMICs. Key strategies include strengthening pathology accuracy through neuropathology partnerships, telepathology, and essential immunohistochemical\/molecular panels; as well as integrating pLGG into national cancer control plans, enabling access to targeted therapies through differential pricing and pooled procurement, and building regional molecular diagnostic hubs. Together, these initiatives can reduce diagnostic errors, expand access to precision medicine, and move LMICs closer to equitable outcomes for children with pLGG.<\/jats:p>","DOI":"10.3389\/fonc.2026.1895650","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T14:08:03Z","timestamp":1787753283000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["\u201cFrom misdiagnosis to precision medicine: strengthening pediatric neuro-oncology care in LMICs toward equitable pLGG outcomes\u201d"],"prefix":"10.3389","volume":"16","author":[{"given":"Lorena V.","family":"Baroni","sequence":"first","affiliation":[{"name":"Division of Oncology, Hospital J. P. Garrahan","place":["Buenos Aires, Argentina"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nichoans B.","family":"George","sequence":"additional","affiliation":[{"name":"Division of Hematology, Oncology, Bone Marrow Transplant & Cellular Therapy, Department of Pediatrics, Seattle Children\u2019s Hospital, University of Washington","place":["Seattle, WA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erin E.","family":"Crotty","sequence":"additional","affiliation":[{"name":"Division of Hematology, Oncology, Bone Marrow Transplant & Cellular Therapy, Department of Pediatrics, Seattle Children\u2019s Hospital, University of Washington","place":["Seattle, WA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Bouffet","sequence":"additional","affiliation":[{"name":"Division of Hematology\/Oncology, Hospital for Sick Children","place":["Toronto, ON, Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed S.","family":"Abdelbaki","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hematology, Oncology and Bone Marrow Transplant, St. Louis Children\u2019s Hospital, Washington University School of Medicine","place":["St. Louis, MO, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30022-X","article-title":"Sustainable care for children with cancer: a Lancet Oncology Commission","volume":"21","author":"Atun","year":"2020","journal-title":"Lancet Oncol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/S2214-109X(23)00053-0","article-title":"Delays in cancer care for children in low-income and middle-income countries: development of a composite vulnerability index","volume":"11","author":"Cotache-Condor","year":"2023","journal-title":"Lancet Glob Health"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.70085","article-title":"Molecular landscape of pediatric low-grade gliomas: insights from RNA-NGS and bioinformatic analysis","volume":"64","author":"Bro\u017e","year":"2025","journal-title":"Genes Chromosomes Cancer"},{"key":"B4","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s40478-020-00902-z","article-title":"Pediatric low-grade glioma in the era of molecular diagnostics","volume":"8","author":"Ryall","year":"2020","journal-title":"Acta Neuropathol Commun"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noaf065","article-title":"A phase 2 PBTC study of selumetinib for recurrent\/progressive pediatric low-grade glioma: strata 2, 5, and 6 with long-term outcomes on strata 1, 3, and 4","volume":"27","author":"Fangusaro","year":"2025","journal-title":"Neuro Oncol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70008-1","article-title":"Paediatric cancer in low-income and middle-income countries","volume":"14","author":"Magrath","year":"2013","journal-title":"Lancet Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30186-9","article-title":"International incidence of childhood cancer, 2001-10: a population-based registry study","volume":"18","author":"Steliarova-Foucher","year":"2017","journal-title":"Lancet Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1200\/GO.22.00199","article-title":"Outcomes of children with low-grade gliomas in low- and middle-income countries: a systematic review","volume":"8","author":"Ward","year":"2022","journal-title":"JCO Glob Oncol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1093\/noajnl\/vdae057","article-title":"Neuro-oncology access in Sub-Saharan Africa: a literature review of challenges and opportunities","volume":"6","author":"Yevudza","year":"2024","journal-title":"Neuro-Oncol Adv"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70007-X","article-title":"New policies to address the global burden of childhood cancers","volume":"14","author":"Sullivan","year":"2013","journal-title":"Lancet Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28958","article-title":"Validated quantitative needs assessment differences in the management of children with central nervous system cancer between Brazil, an upper middle-income country, and the United States of America, a high income country","volume":"68","author":"Fischer","year":"2021","journal-title":"Pediatr Blood Cancer"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00463-0","article-title":"Access to cancer medicines deemed essential by oncologists in 82 countries: an international, cross-sectional survey","volume":"22","author":"Fundytus","year":"2021","journal-title":"Lancet Oncol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.60.6376","article-title":"Toward the cure of all children with cancer through collaborative efforts: pediatric oncology as a global challenge","volume":"33","author":"Rodriguez-Galindo","year":"2015","journal-title":"J Clin Oncol"},{"key":"B14","volume-title":"Cureall Framework: WHO Global Initiative for Childhood Cancer: Increasing Access, Advancing Quality, Saving Lives","year":"2021"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2024.101098","article-title":"Pediatric neuro-oncology: highlights of the last quarter-century","volume":"59","author":"Power","year":"2025","journal-title":"Neoplasia"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2024.5506","article-title":"Molecular testing for the World Health Organization classification of central nervous system tumors: a review","volume":"11","author":"Horbinski","year":"2025","journal-title":"JAMA Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro Oncol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-022-01249-0","article-title":"Major features of the 2021 WHO classification of CNS tumors","volume":"19","author":"Smith","year":"2022","journal-title":"Neurotherapeutics"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1997","DOI":"10.1016\/S0140-6736(21)00673-5","article-title":"The Lancet Commission on diagnostics: transforming access to diagnostics","volume":"398","author":"Fleming","year":"2021","journal-title":"Lancet"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/bs.acr.2025.08.004","article-title":"Management of pediatric brain tumors in low- and middle-income countries","volume":"167","author":"Amayiri","year":"2025","journal-title":"Adv Cancer Res"},{"key":"B21","doi-asserted-by":"publisher","first-page":"S0007","DOI":"10.1016\/j.bulcan.2025.11.012","article-title":"Le d\u00e9veloppement de la neuro-oncologie p\u00e9diatrique en Afrique francophone : \u00e9tat des lieux et d\u00e9fis [Pediatric neuro-oncology in French-speaking Africa: Current status and challenges","author":"Bouffet","year":"2026","journal-title":"Bull Cancer"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1328374","article-title":"Pediatric neuropathology practice in a low- and middle-income country: capacity building through institutional twinning","volume":"14","author":"Gilani","year":"2024","journal-title":"Front Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26709","article-title":"Pediatric cancer pathology review from a single institution: neuropathology expert opinion is essential for accurate diagnosis of pediatric brain tumors","volume":"65","author":"Merabi","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"B24","first-page":"Chapter 7","article-title":"Treating childhood cancer in low- and middle-income countries","volume-title":"Cancer: Disease Control Priorities","author":"Gupta","year":"2015"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nox141","article-title":"Pediatric low-grade gliomas: next biologically driven steps","volume":"20","author":"Jones","year":"2018","journal-title":"Neuro Oncol"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noae008","article-title":"A paradigm shift in how we treat pediatric low-grade glioma-targeting the molecular drivers","volume":"26","author":"Ziegler","year":"2024","journal-title":"Neuro Oncol"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1503894","article-title":"The role of MEK inhibition in pediatric low-grade gliomas","volume":"14","author":"Sheikh","year":"2024","journal-title":"Front Oncol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"4343","DOI":"10.1038\/s41467-019-12187-5","article-title":"Alterations in ALK\/ROS1\/NTRK\/MET drive a group of infantile hemispheric gliomas","volume":"10","author":"Guerreiro Stucklin","year":"2019","journal-title":"Nat Commun"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1007\/s00401-016-1539-z","article-title":"Genetic alterations in uncommon low-grade neuroepithelial tumors: BRAF, FGFR1, and MYB mutations occur at high frequency and align with morphology","volume":"131","author":"Qaddoumi","year":"2016","journal-title":"Acta Neuropathol"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1016\/j.neo.2022.100857","article-title":"Pediatric low-grade glioma: targeted therapeutics and clinical trials in the molecular era","volume":"36","author":"Manoharan","year":"2023","journal-title":"Neoplasia"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2303815","article-title":"Dabrafenib plus Trametinib in pediatric glioma with BRAF V600 mutations","volume":"389","author":"Bouffet","year":"2023","journal-title":"N Engl J Med"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02668-y","article-title":"The type II RAF inhibitor tovorafenib in relapsed\/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial","volume":"30","author":"Kilburn","year":"2024","journal-title":"Nat Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1007\/s00381-024-06639-7","article-title":"Molecular markers for pediatric low-grade glioma","volume":"40","author":"Levine","year":"2024","journal-title":"Childs Nerv Syst"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1520316","article-title":"Integrating MAPK pathway inhibition into standard-of-care therapy for pediatric low-grade glioma","volume":"15","author":"Crotty","year":"2025","journal-title":"Front Oncol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(19)30277-3","article-title":"Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial","volume":"20","author":"Fangusaro","year":"2019","journal-title":"Lancet Oncol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1097\/MOP.0000000000000573","article-title":"Pediatric palliative oncology: the state of the science and art of caring for children with cancer","volume":"30","author":"Snaman","year":"2018","journal-title":"Curr Opin Pediatr"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1417484","article-title":"BRAF\/MEK inhibitors use for pediatric gliomas; real world experience from a resource-limited country","volume":"14","author":"Abu Laban","year":"2024","journal-title":"Front Oncol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noae064.744","article-title":"MEK inhibitors in pediatric low-grade gliomas (PLGG)- early experience in a resource limited setting","volume":"26","author":"Chinnaswamy","year":"2024","journal-title":"Neuro-Oncology"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.34172\/ijhpm.2020.144","article-title":"Ethical and social values for paediatric health technology assessment and drug policy","volume":"11","author":"Denburg","year":"2022","journal-title":"Int J Health Policy Manage"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2017.31","article-title":"The high price of anticancer drugs: origins, implications, barriers, solutions","volume":"14","author":"Prasad","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"B41","volume-title":"Expanding Access to Cancer Medicines in Lmics","year":"2024"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.3389\/fcacs.2025.1528695","article-title":"Pediatric low-grade glioma in Africa: a baseline study before the implementation of Global Initiative for Childhood Cancer strategies","volume":"3","author":"Van Heerden","year":"2025","journal-title":"Front Cancer Control Soc"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.3171\/2017.11.JNS171500","article-title":"Global neurosurgery: the current capacity and deficit in the provision of essential neurosurgical care. Executive summary of the Global Neurosurgery Initiative at the Program in Global Surgery and Social Change","volume":"130","author":"Dewan","year":"2018","journal-title":"J Neurosurg"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1325167","article-title":"Capacity building for pediatric neuro-oncology in Pakistan- a project by my child matters program of Foundation S","volume":"14","author":"Mushtaq","year":"2024","journal-title":"Front Oncol"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.29887","article-title":"Impact of dedicated pediatric neuro-oncological services in a developing country: a single-institution, Pakistani experience","volume":"69","author":"Hamid","year":"2022","journal-title":"Pediatr Blood Cancer"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-025-02793-3","article-title":"Collaborative frontiers in pediatric neuro-oncology: establishing an international tumor board for enhanced care and global impact","volume":"30","author":"Shatara","year":"2025","journal-title":"Int J Clin Oncol"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nov187","article-title":"A new clinical guideline from the Royal College of Paediatrics and Child Health with a national awareness campaign accelerates brain tumor diagnosis in UK children--\"HeadSmart: Be Brain Tumour Aware","volume":"18","year":"2016","journal-title":"Neuro Oncol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1080\/23288604.2016.1124167","article-title":"The international right to health: What does it mean in legal practice and how can it affect priority setting for universal health coverage","volume":"2","author":"Dittrich","year":"2016","journal-title":"Health Syst Reform"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-3-031-36785-4_1","article-title":"The greatest healthcare disparity: addressing inequities in the treatment of childhood central nervous system tumors in low- and middle-income countries","volume":"48","author":"Roach","year":"2023","journal-title":"Adv Tech Stand Neurosurg"},{"key":"B50","article-title":"Telepathology in global health: expanding access to expert diagnosis","volume":"7","author":"Igor","year":"2025","journal-title":"J Surg Path Diag"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1200\/GO-25-00023","article-title":"Expanding the pediatric neuro-oncology teleconference experience: from twinning to international cases discussions","volume":"11","author":"Al Badarin","year":"2025","journal-title":"JCO Glob Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1895650\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T14:08:05Z","timestamp":1787753285000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1895650\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,26]]},"references-count":51,"alternative-id":["10.3389\/fonc.2026.1895650"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1895650","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,26]]},"article-number":"1895650"}}